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Introduction {#sec006}
============

Until 2003, investigators in Japan could not conduct clinical trials individually, whether to investigate a new medicine or a new application of approved drugs or even to research theories or promising treatments. Companies carried out such studies and then submitted an investigational new drug (IND) application to the Ministry of Health, Labour, and Welfare (MHLW). Amendment of the Pharmaceutical Affairs Law in July 2002 permitted investigators to apply for INDs in July 2003, thus marking the start of investigator-initiated trials (IITs) in Japan. However, the number of IIT applications for INDs remained quite small at about 60 from 2004 to 2010 \[[@pone.0148455.ref001]\]. About half of these were trials for new applications of an approved drug, using funding schemes for the Clinical Trial Grant Program of the Japan Medical Association Center for Clinical Trials (JMACCT) \[[@pone.0148455.ref002]\]. The other half was trials proposed by the author, to investigate a new drug or device in an early-phase study with a small number participants and using government funding schemes or institutional budgets. The reasons for the small number of IITs during this period include few funding opportunities and a poor quality assurance structure \[[@pone.0148455.ref003]\]. A review of [ClinicalTrials.gov](http://ClinicalTrials.gov), one of the largest open registries of publicly and privately supported clinical trials worldwide, showed that there were over 7,000, registered studies from 2000 to 2010 sponsored by the United States National Institutes of Health (NIH) and US government agencies and excluding industry, which includes the majority of IITs \[[@pone.0148455.ref004]\]. These results highlight a large difference between Japan and other countries in terms of numbers of IITs. Key factors that may contribute to increasing IITs in Japan might be found by investigating IITs registered in [ClinicalTrials.gov](http://ClinicalTrials.gov). Califf et al. found that trials registered in [ClinicalTrials.gov](http://ClinicalTrials.gov) exhibited heterogeneity in their methodological approaches, and that sponsored-identified trials accounted for a total of 40% of registered trials from 2007 to 2010 \[[@pone.0148455.ref004]\]. However, no studies have focused on IITs sponsored by academic or government institutions. Thus, the purpose of this study is to identify differences between Japan and other countries through analyzing the characteristics of trials sponsored by academia or government in the [ClinicalTrials.gov](http://ClinicalTrials.gov) database and sponsored-identified IITs in the three Japanese registries database.

The [ClinicalTrials.gov](http://ClinicalTrials.gov) registry was established in 2000 by the National Library of Medicine on behalf of the NIH. [ClinicalTrials.gov](http://ClinicalTrials.gov) is a publicly available clinical trial registry and results database. Data are self-reported by sponsors via a web-based system. Any sponsor, principal investigator, or other person or organization with primary responsibility for a trial can register trials in the database. The registry includes mandatory and optional data elements such as the trial purpose, phase, enrolled participants, age group, participant sex, masking, trial assignment, number of arms, treatment allocation, and trial control groups. [ClinicalTrials.gov](http://ClinicalTrials.gov) is a not only an integrated database for clinical trials but also a useful tool to visualize trends in current trials. In 2004, the International Committee of Medical Journal Editors (ICMJE) initiated a policy requiring registration of clinical trials as a prerequisite for publication \[[@pone.0148455.ref005]\]. In the United States, the Food and Drug Administration Amendment Acts of 2007 requires sponsors to register clinical trials in a database \[[@pone.0148455.ref006]\]. This amendment resulted in a sharp increase in the number of trials registered in [ClinicalTrials.gov](http://ClinicalTrials.gov).

In Japan, the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) was begun in June 2005, as the first Japanese registry accepted by the ICMJE. The second registry site, the Japan Pharmaceutical Information Center Clinical Trials Information (JapicCTI), was established in July 2005 and the third, the Japan Medical Association Center for Clinical Trials, Clinical Trials Registry (JMACCT CTR), in December 2005 \[[@pone.0148455.ref007]\]. The three registries are publicly available. Data are self-reported by sponsors. All three Japanese registries include elements included in [ClinicalTrials.gov](http://ClinicalTrials.gov), such as trial purpose, study type, study design, phase, enrolled participants, age group, participant sex, trial masking, trial assignment, number of arms, treatment allocation, and trial control groups. Under its funding rules of 2009, sponsors must register clinical trials funded by the MHLW in a trial database.

The methods used in this study are described in Section 2 (Materials and Methods). Section 3 (Results) elaborates all analyzed trials for 2010 and characterization according to three therapeutic areas. Discussion is presented in Section 4 (Discussion) and conclusions in Section 5 (Conclusion).

Materials and Methods {#sec007}
=====================

Data of new or revised trials registered with [ClinicalTrials.gov](http://ClinicalTrials.gov) in 2010 were collected through Thomson Reuters Pharma™, a data source for pharmaceutical information owned by Thomson Reuters, which enables clinical trial data to be downloaded as a whole. Data of new IITs registered from 2004 to 2012 in Japan were collected via the UMIN-CTR, JapicCTI, and JMACCT CTR registry sites.

Data set {#sec008}
--------

Over 100,000 clinical trials were registered in [ClinicalTrials.gov](http://ClinicalTrials.gov) during 2010. Here, a total 88,819 trials were chosen via Thomson Reuters Pharma, by focusing on the main therapeutic areas including cardiovascular, endocrine, gastrointestinal, immunological, infectious, inflammatory, neoplasm, neurological, and respiratory diseases. This data set was downloaded from Thomson Reuters Pharma, between 25 and 28 March 2011, to facilitate aggregate analysis. Data were included in two XML data files comprising 88,819 clinical trials in total and 1,943 sponsor-identified trials, grouped according to three therapeutic areas: cardiovascular diseases, brain diseases within neurological diseases, and endocrine tumors within neoplasms. The reason for choosing these three disease areas is that it was of interest to the author to determine trends of trials in these treatment areas, having worked as a clinical trial manager with clinicians in these specialties. A total 38,003 new or revised trials, registered from 1 January to 31 December 2010, were extracted from the total 88,819 trials. Extracted trials were further categorized into sponsor-identified and non-sponsor-identified trials.

In line with the organization authority file of Thomson Reuters Pharma, sponsors were defined by organization type: academic institution, government, company, collective investment, government department or agency, market participant, non-government organization, supranational, or unknown. For instance, if the lead sponsoring organization was a university or research institute, the organization type was categorized as an academic institution. If the lead sponsor was a private company, small- to medium-sized enterprise, or start-up company, this was categorized as a company. Nearly 70% of all trials had a currently identified sponsoring organization in accordance with the organization authority file. Sponsor-identified trials were then divided into two categories, academia and government (A&G) or industry; all A&G sponsor-identified trials (A&G trials) here were IITs. If trials included both an academic institution and industry outfit as a sponsor and a collaborator, they were defined as sponsored by both. Data of A&G trials that had been classified as neurological diseases and neoplasms were regrouped into brain diseases and endocrine tumors, respectively. Within these therapeutic specialty data sets, a few data elements were missing because of limitations in the data set or logistical problems in obtaining analyzable information. For this regrouping, an index by Thomson Reuters Pharma was used to create specialty data sets.

A data set of IITs conducted under Good Clinical Practice (GCP) guidelines in Japan was collected using information in the UMIN, JAPIC or JMACCT registries. An IIT was defined as an IND application trial conducted by investigators, based on governmental funding program information, clinical trial information of the MHLW and JMACCT, or clinical trial information on websites of universities, hospitals, and research institutes. The IITs were also found on either the UMIN-CTR, JapicCTI, or JMACCT CTR sites. Because the number of trials in only 2010 was too small to compare with trials in [ClinicalTrials.gov](http://ClinicalTrials.gov) in the same year, all IITs in Japan during an 8-year period between January 2004 and March 2012 were analyzed. These data were collected from 1 April 2011 to 31 March 2012 and comprised a total of 56 trials.

Analytical methods {#sec009}
------------------

From the [ClinicalTrials.gov](http://ClinicalTrials.gov) database, the three main therapeutic areas of clinical trial data (brain diseases within neurological diseases, cardiovascular diseases, and endocrine tumors within neoplasms) were characterized and analyzed, using a model containing 11 characteristics: study type (interventional or observational); purpose (treatment, basic science, diagnostic, health services, natural history, prevention, screening, supportive care, training, and other); phase (0, 1, 1/2, 1b, 2, 2/3, 2a, 2b, 3, 3b, 4); number of enrolled participants (\<5, 5--10, 10--20, 20--50, 50--100, 100--200, 200--500, and \>500); trial age group (children, adults, older adults, or all ages); trial masking (open-label, single-blind, or double-blind); trial assignment (single, parallel, crossover, or factorial); number of arms (1, 2, 3, 4, 5, or 6); trial allocation (randomized or non-randomized); trial control (placebo, active, dose comparison, historical, or uncontrolled); and sex of the study population (male, female, or both).

All Japanese IIT from 2004 to 2012 were characterized and analyzed, using a model containing 11 characteristics: study type (interventional or observational); purpose (treatment, prevention, pharmacokinetics, and others); phase (1, 1/2, 2, 2/3, 3 or 4); number of enrolled participants (\<5, 5--10, 10--20, 20--50, 50--100, 100--200, 200--500 or \>500); trial age group (children, adults, older adults, or all ages); trial masking (open-label, single-blind, or double-blind); trial assignment (single, parallel or factorial); number of arms (1, 2, 3, 4 or 5); trial allocation (randomized or non-randomized); trial control (placebo, active, dose comparison, historical or uncontrolled); and sex (male, female, or both).

Cross analyses were then performed between trial purpose and phase, between trial purpose and participants, and between trial phase and participants using [ClinicalTrials.gov](http://ClinicalTrials.gov) data and Japanese registry data, respectively.

All assessments are described as a number or a percentage. Statistical analysis software was not used in this study.

Results {#sec010}
=======

A total 38,003 of 88,819 new or revised clinical trials registered in [ClinicalTrials.gov](http://ClinicalTrials.gov) in 2010 were extracted ([Table 1](#pone.0148455.t001){ref-type="table"}). Of these, 29,200 (76.8%) were identified as trials sponsored by an organization. There were 11,737 (40.2%) A&G trials. By contrast, industry-sponsored trials accounted for 19,638 (67.3%). Between 5.5% and 9.2% of trials for each therapeutic group were A&G and industry-sponsored trials. When examining all trials registered in [ClinicalTrials.gov](http://ClinicalTrials.gov) in 2010, neoplasm trials had the highest ratios, accounting for 4,705 of 8,132 (57.9%) of A&G trials. The highest number of industry-sponsored trials was for inflammatory disease, with 1,847/2,169 (85.2%).

10.1371/journal.pone.0148455.t001

###### Characteristics of Studies Registered in [ClinicalTrials.gov](http://ClinicalTrials.gov) During 2010.
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                                 All Studies   Newly Registered or Revised Studies   With Sponsor   With Sponsor (%)   Academic and Government Sponsored Studies   Academic and Government Sponsored Studies (%)   Industry-Sponsored Studies   Industry Sponsored Studies (%)   Both (%)
  ------------------------------ ------------- ------------------------------------- -------------- ------------------ ------------------------------------------- ----------------------------------------------- ---------------------------- -------------------------------- ----------
  **Cardiovascular Disease**     5779          2492                                  1781           71.5%              599                                         33.6%                                           1321                         74.2%                            7.8%
  **Endocrine Disease**          8166          3542                                  2819           79.6%              1072                                        38.0%                                           1933                         68.6%                            6.6%
  **Gastrointestinal Disease**   11451         4906                                  3772           76.9%              1372                                        36.4%                                           2660                         70.5%                            6.9%
  **Immunological Disease**      8879          3615                                  2870           79.4%              1110                                        38.7%                                           1968                         68.6%                            7.2%
  **Infection**                  9240          3775                                  2608           69.1%              793                                         30.4%                                           2022                         77.5%                            7.9%
  **Inflammatory Disease**       7156          2857                                  2169           75.9%              450                                         20.7%                                           1847                         85.2%                            5.9%
  **Neoplasm**                   22940         10077                                 8132           80.7%              4705                                        57.9%                                           4178                         51.4%                            9.2%
  **Neurological Disease**       7973          3537                                  2667           75.4%              907                                         34.0%                                           1908                         71.5%                            5.5%
  **Respiratory Disease**        7235          3202                                  2382           74.4%              729                                         30.6%                                           1801                         75.6%                            6.2%
  **Total**                      88819         38003                                 29200          76.8%              11737                                       40.2%                                           19638                        67.3%                            

The number of A&G trials in the three therapeutic areas investigated was 385, 559, and 959 for brain disease, cardiovascular disease, and endocrine tumors, respectively ([Table 2](#pone.0148455.t002){ref-type="table"}). The study type was interventional for all three therapeutic specialties, and the purpose was mostly treatment. The number of prevention trials for cardiovascular disease, 78/599 (13%), was higher than for the other two areas. Phases 0 through 2 accounted for over 60% and 80% for brain diseases and endocrine tumors trials, respectively; however, these phases represented only about 35% of cardiovascular trials. The category of 20--50 enrolled participants was most frequent for the three therapeutic areas: 125/385 (32.5%), 147/599 (24.5%), and 365/959 (38.1%) for brain disease, cardiovascular disease, and endocrine tumors, respectively. Interestingly, cardiovascular disease trials had the largest sized trials, with 200--500 (83/599, 13.9%) and \>500 (75/599, 12.5%) enrolled participants. The adult age group was the most frequent of all groups, but there were 67/385 (17.4%) brain disease trials conducted in children. Masking was completely different among the three trial areas. Open-label was the most frequent for brain disease and endocrine tumor trials, with 165/385 (42.9%) and 598/959 (62.4%), respectively. However, double-blind was most prevalent in cardiovascular disease trials, with 275/599 (45.9%). Assignment also differed among the three therapeutic areas. In brain disease trials, single and parallel groups accounted for 88/385 (22.9%) and 93/385 (24.2%), respectively, however, missing data represented about half of brain disease trials, or 187/385 (48.6%). In cardiovascular disease trials, parallel groups accounted for 314/599 (52.4%). In endocrine tumor trials, single groups accounted for 282/959 (29.4%), but missing data accounted for 587/959 (61.2%) trials. Trial arms were predominantly (with about 60%) one- and two-armed trials among the three therapeutic areas. One-armed trials were the most frequent among brain disease and endocrine tumor trials, with 116/385 (30.1%) and 409/959 (42.6%), respectively. In cardiovascular disease trials, two-armed trials accounted for 275/599 (45.9%). Allocation differed by specialty. Cardiovascular disease trials were mostly randomized, with 472/599 (78.8%), whereas brain disease and endocrine tumor trials were less so, with 142/385 (36.9%) and 255/959 (26.6%), respectively. However, there were missing data for about 50% of trials for the latter two specialties. The trial control was also different among these areas. Brain disease and cardiovascular disease trials were mostly conducted using placebo controls, with 83/385 (21.6%) and 245/599 (40.9%), respectively. Endocrine tumor trials were mostly performed using active controls, with 133/959 (13.9%). However, over 50% of brain disease and endocrine tumor trials had missing data. Trials included both sexes, except for endocrine tumor trials; half of these were for breast or ovarian cancers and therefore included only females.

10.1371/journal.pone.0148455.t002

###### Characteristics of A&G Studies Registered in [ClinicalTrials.gov](http://ClinicalTrials.gov) During 2010.
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                                        Brain Disease within Neurological Disease (%) (n = 385)   Cardiovascular Disease (%) (n = 599)   Endocrine Tumor within Neoplasm (%) (n = 959)   
  ------------------------------------- --------------------------------------------------------- -------------------------------------- ----------------------------------------------- ------------
  **Study Type**                        **Interventional**                                        374 (97.1)                             580 (96.8)                                      948 (98.9)
                                        **Observational**                                         11 (2.9)                               18 (3.0)                                        10 (1.0)
                                        **Missing**                                               0 (0.0)                                1 (0.2)                                         1 (0.1)
  **Purpose**                           **Treatment**                                             337 (87.5)                             460 (76.8)                                      890 (92.8)
                                        **Basic Science**                                         3 (0.8)                                12 (2.0)                                        3 (0.3)
                                        **Diagnostic**                                            7 (1.8)                                17 (2.8)                                        12 (1.3)
                                        **Health Services**                                       1 (0.3)                                0 (0.0)                                         0 (0.0)
                                        **Natural History**                                       1 (0.3)                                0 (0.0)                                         0 (0.0)
                                        **Other**                                                 0 (0.0)                                4 (0.7)                                         1 (0.1)
                                        **Prevention**                                            18 (4.7)                               78 (13.0)                                       22 (2.3)
                                        **Screening**                                             3 (0.8)                                3 (0.5)                                         2 (0.2)
                                        **Supportive Care**                                       8 (2.1)                                8 (1.3)                                         18 (1.9)
                                        **Training**                                              0 (0.0)                                0 (0.0)                                         1 (0.1)
                                        **Missing**                                               7 (1.8)                                17 (2.8)                                        10 (1.0)
  **Phase**                             **Phase 0**                                               1 (0.3)                                5 (0.8)                                         4 (0.4)
                                        **Phase 1**                                               75 (19.5)                              32 (5.3)                                        192 (20.0)
                                        **Phase 1/2**                                             42 (10.9)                              32 (5.3)                                        97 (10.1)
                                        **Phase 2**                                               116 (30.1)                             87 (14.5)                                       479 (49.9)
                                        **Phase 2/3**                                             10 (2.6)                               24 (4.0)                                        7 (0.7)
                                        **Phase 3**                                               33 (8.6)                               82 (13.7)                                       122 (12.7)
                                        **Phase 4**                                               34 (8.8)                               134 (22.4)                                      6 (0.6)
                                        **Phase Not Specified**                                   74 (19.2)                              200 (33.4)                                      52 (5.4)
                                        **Missing**                                               0 (0.0)                                3 (0.5)                                         0 (0.0)
  **Number of Enrolled Participants**   **\<5**                                                   5 (1.3)                                8 (1.3)                                         13 (1.4)
                                        **5--10**                                                 10 (2.6)                               9 (1.5)                                         15 (1.6)
                                        **10--20**                                                55 (14.3)                              47 (7.8)                                        66 (6.9)
                                        **20--50**                                                125 (32.5)                             147 (24.5)                                      365 (38.1)
                                        **50--100**                                               85 (22.1)                              125 (20.9)                                      242 (25.2)
                                        **100--200**                                              38 (9.9)                               89 (14.9)                                       84 (8.8)
                                        **200--500**                                              29 (7.5)                               83 (13.9)                                       49 (5.1)
                                        **\>500**                                                 15 (3.9)                               75 (12.5)                                       81 (8.4)
                                        **Missing**                                               23 (6.0)                               16 (2.7)                                        44 (4.6)
  **Trial Age Group**                   **Children (0--17 y)**                                    67 (17.4)                              37 (6.2)                                        11 (1.1)
                                        **Adults (18--65 y)**                                     262 (68.1)                             468 (78.1)                                      820 (85.5)
                                        **Older adults (66+ y)**                                  9 (2.3)                                3 (0.5)                                         5 (0.5)
                                        **All ages**                                              7 (1.8)                                0 (0.0)                                         0 (0.0)
                                        **Missing**                                               40 (10.4)                              91 (15.2)                                       123 (12.8)
  **Trial Masking**                     **Open-label**                                            165 (42.9)                             212 (35.4)                                      598 (62.4)
                                        **Single-blind**                                          11 (2.9)                               47 (7.8)                                        5 (0.5)
                                        **Double-blind**                                          99 (25.7)                              275 (45.9)                                      49 (5.1)
                                        **Missing**                                               110 (28.6)                             65 (10.9)                                       307 (32.0)
  **Trial Assignment**                  **Single Group**                                          88 (22.9)                              95 (15.9)                                       282 (29.4)
                                        **Parallel**                                              93 (24.2)                              314 (52.4)                                      82 (8.6)
                                        **Crossover**                                             15 (3.9)                               58 (9.7)                                        8 (0.8)
                                        **Factorial**                                             2 (0.5)                                14 (2.3)                                        0 (0.0)
                                        **Missing**                                               187 (48.6)                             118 (19.7)                                      587 (61.2)
  **Number of Arms**                    **1**                                                     116 (30.1)                             92 (15.4)                                       409 (42.6)
                                        **2**                                                     96 (24.9)                              275 (45.9)                                      145 (15.1)
                                        **3**                                                     14 (3.6)                               52 (8.7)                                        35 (3.6)
                                        **4**                                                     7 (1.8)                                21 (3.5)                                        11 (1.1)
                                        **5**                                                     1 (0.3)                                1 (0.2)                                         3 (0.3)
                                        **6**                                                     1 (0.3)                                4 (0.7)                                         2 (0.2)
                                        **Missing**                                               150 (39.0)                             154 (25.7)                                      354 (36.9)
  **Trial Allocation**                  **Randomized**                                            142 (36.9)                             472 (78.8)                                      255 (26.6)
                                        **Non-randomized**                                        52 (13.5)                              52 (8.7)                                        218 (22.7)
                                        **Missing**                                               191 (49.6)                             75 (12.5)                                       486 (50.7)
  **Trial Control**                     **Placebo Control**                                       83 (21.6)                              245 (40.9)                                      44 (4.6)
                                        **Active Control**                                        39 (10.1)                              131 (21.9)                                      133 (13.9)
                                        **Dose Comparison**                                       13 (3.4)                               25 (4.2)                                        19 (2.0)
                                        **Historical Control**                                    4 (1.0)                                6 (1.0)                                         21 (2.2)
                                        **Uncontrolled**                                          24 (6.2)                               41 (6.8)                                        73 (7.6)
                                        **Missing**                                               222 (57.7)                             151 (25.2)                                      669 (69.8)
  **Sex**                               **Female Only**                                           8 (2.1)                                34 (5.7)                                        468 (48.8)
                                        **Male Only**                                             4 (1.0)                                22 (3.7)                                        7 (0.7)
                                        **Both**                                                  373 (96.9)                             543 (90.7)                                      484 (50.5)

According to cross-analysis between trial purposes and phases, most brain disease and endocrine tumor trials were for treatment and from early phase through phase 2 ([Fig 1](#pone.0148455.g001){ref-type="fig"}). Cardiovascular disease trials for the purpose of treatment showed two peaks, one for early phase (phases 1 to 2) and another for late phase (phases 3 to 4) trials. In the cross-analysis between trial purpose and participants, all three therapeutic areas were dominated by low enrollment numbers (20--50 participants) and were for the purpose of treatment ([Fig 2](#pone.0148455.g002){ref-type="fig"}). Cross-analysis between trial phases and participants identified that A&G trials were nearly all early phase (through phase 2) with fewer than 100 enrolled participants ([Fig 3](#pone.0148455.g003){ref-type="fig"}). However, in all three specialties, there were also some peaks in late-phase trials with large enrollment.

![Cross-analyses between trial purpose and phase in [ClinicalTrials.gov](http://ClinicalTrials.gov).\
Curve areas represent the number of trials across the phase and the trial purposes, for brain diseases, cardiovascular disease, and endocrine tumors, respectively.](pone.0148455.g001){#pone.0148455.g001}

![Cross-analyses between trial purpose and participants in [ClinicalTrials.gov](http://ClinicalTrials.gov).\
Curve areas represent the number of trials across the participants and the trial purposes, for brain diseases, cardiovascular disease, and endocrine tumor, respectively.](pone.0148455.g002){#pone.0148455.g002}

![Cross-analyses between trial participants and phase in [ClinicalTrials.gov](http://ClinicalTrials.gov).\
Curve areas represent the number of trials across the phase and the participants, for brain diseases, cardiovascular disease, and endocrine tumor, respectively.](pone.0148455.g003){#pone.0148455.g003}

In Japan, IITs under GCP began in 2004. A total of 56 IITs were found over the 8 years from January 2004 to March 2012 in the three Japanese registries ([Fig 4](#pone.0148455.g004){ref-type="fig"}). There were 29, 24, and three IITs identified in the UMIN-CTR, JMACCT CTR, and JapicCTI registries, respectively. The number of IITs subsequently showed a slight annual increase, despite decreasing for 2 years between 2006 and 2007. [Table 3](#pone.0148455.t003){ref-type="table"} shows the characteristics of the 56 identified IITs, analyzed according to the 11 categories. The study type was dominated by interventional for all trials, and the purpose was mostly treatment. The number of prevention trials and pharmacokinetics trials were as follows: four influenza vaccine studies, and three phase 1 and 1/2 studies during the study period, respectively. Phases 1 to 2 accounted for around 50% of all trials, and phase 3 trials represented 12/56 (21.4%). Studies in which the phase was not specified were the mostly exploratory trials of medical devices. The category of 20--50 enrolled participants was the most frequent, with 26/56 (46.4%). Trial age groups varied widely, but children, adults and older adults were the groups most frequently represented, together accounting for 21/56 (37.5%). Open-label was the most frequent type of trials masking, with 42/56 (75.0%). Assignment was predominantly single with 33/56 (58.9%) and parallel with 21/56 (35.7%). Trial arms were mostly one-armed trials with 32/56 (57.1%) and two-armed trials with 19/56 (33.9%). Allocation was dominated by non-randomized trials with 35/56 (62.5%), followed by randomized trials with 20/56 (35.7%). In terms of the trial control, uncontrolled studies were the most prevalent with 33/56 (58.9%), followed by placebo-control with 7/56 (12.5%), active control with 6/56 (10.7%), dose comparison with 7/56 (10.7%), and historical control with 4/56 (7.1%). Most trials included both sexes nearly equally, except for female-only breast or ovarian cancer trials and male-only trials for male hormonal disorders and pharmacokinetics.

![Number of investigator-initiated trials in Japanese registries.\
Curve represents the number of investigator-initiated trials from 2004 to 2012.](pone.0148455.g004){#pone.0148455.g004}

10.1371/journal.pone.0148455.t003

###### Characteristics of Investigator Initiated Trials Registered in Japan from 2004 to 2012.
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                                                                                        Number of IIT (%) (n = 56)
  ------------------------------------- ----------------------------------------------- ----------------------------
  **Study Type**                        **Interventional**                              55 (98.2)
                                        **Observational**                               1 (1.8)
  **Purpose**                           **Treatment**                                   48 (85.7)
                                        **Prevention**                                  4 (7.1)
                                        **Pharmacokinetic**                             3 (5.4)
                                        **Other**                                       1 (1.8)
  **Phase**                             **Phase 1**                                     4 (7.1)
                                        **Phase 1/2**                                   5 (8.9)
                                        **Phase 2**                                     19 (33.9)
                                        **Phase 2/3**                                   9 (16.1)
                                        **Phase 3**                                     12 (21.4)
                                        **Phase 4**                                     0 (0.0)
                                        **Not specified**                               7 (12.5)
  **Number of Enrolled Participants**   **\<5**                                         1 (1.8)
                                        **5--10**                                       1 (1.8)
                                        **10--20**                                      9 (16.1)
                                        **20--50**                                      26 (46.4)
                                        **50--100**                                     5 (8.9)
                                        **100--200**                                    8 (14.3)
                                        **200--500**                                    6 (10.7)
                                        **\>500**                                       0 (0.0)
  **Trial Age Group**                   **Children (0--17)**                            7 (12.5)
                                        **Children and Adults (0--65)**                 1 (1.8)
                                        **Children, Adults and Older adults (0--75)**   21 (37.5)
                                        **Adults (20--65)**                             9 (16.1)
                                        **Adults and Older adults (20--84)**            15 (26.8)
                                        **Older adults (66+y)**                         0 (0.0)
                                        **All ages**                                    2 (3.6)
                                        **Missing**                                     1 (1.8)
  **Trial Masking**                     **Open-label**                                  42 (75.0)
                                        **Single-blind**                                4 (7.1)
                                        **Double-blind**                                10 (17.9)
  **Trial Assignment**                  **Single Group**                                33 (58.9)
                                        **Parallel**                                    21 (37.5)
                                        **Factorial**                                   1 (1.8)
                                        **Missing**                                     1 (1.8)
  **Number of Arms**                    **1**                                           32 (57.1)
                                        **2**                                           19 (33.9)
                                        **3**                                           2 (3.6)
                                        **4**                                           1 (1.8)
                                        **5**                                           1 (1.8)
                                        **Missing**                                     1 (1.8)
  **Trial Allocation**                  **Randomized**                                  20 (35.7)
                                        **Non-randomized**                              35 (62.5)
                                        **Missing**                                     1 (1.8)
  **Trial Control**                     **Placebo Control**                             7 (12.5)
                                        **Active Control**                              6 (10.7)
                                        **Dose Comparison**                             6 (10.7)
                                        **Historical Control**                          4 (7.1)
                                        **Uncontrolled**                                33 (58.9)
  **Sex**                               **Female Only**                                 7 (12.5)
                                        **Male Only**                                   3 (5.4)
                                        **Both**                                        46 (82.1)

Regarding cross-analysis between trial purposes and phases, most trials were for treatment and from early phase through phase 2 ([Fig 5](#pone.0148455.g005){ref-type="fig"}). In the cross-analysis between trial purpose and participants, trials were dominated by those with low enrollment numbers (up to 20--50 participants) and were for the purpose of treatment ([Fig 6](#pone.0148455.g006){ref-type="fig"}). Cross-analysis between trial phases and participants identified that nearly all trials were early phase (through phase 2) with fewer than 100 enrolled participants ([Fig 7](#pone.0148455.g007){ref-type="fig"}). However, there were also some peaks in late-phase trials.

![Cross-analyses between trial purpose and phase in Japanese registries.\
Curve areas represent the number of trials across the phase and the trial purposes.](pone.0148455.g005){#pone.0148455.g005}

![Cross-analyses between trial purpose and participants in Japanese registries.\
Curve areas represent the number of trials across participants and the trial purposes.](pone.0148455.g006){#pone.0148455.g006}

![Cross-analyses between trial participants and phase in Japanese registries.\
Curve areas represent the number of trials across phase and the participants.](pone.0148455.g007){#pone.0148455.g007}

Discussion {#sec011}
==========

To identify differences between Japan and other countries regarding IITs with academic or government sponsors, this study investigated the characteristics of newly registered or revised sponsor-identified trials in [ClinicalTrials.gov](http://ClinicalTrials.gov) in 2010, as compared with characteristics of newly registered IITs in the UMIN-CTR, JapicCTI or JMACCT CTR registries from 2004 to 2012.

First, sponsor-identified trials represented over 75% of all trials registered with [ClinicalTrials.gov](http://ClinicalTrials.gov) in 2010, and A&G trials accounted for about 40% of all sponsor-identified trials. The number of A&G trials was lower than that of industry-sponsored trials. Interestingly, each therapeutic area had different percentages of trials sponsored by A&G and industry. Neoplasm trials had the most A&G trials with 57.9%, which represents efforts by academia to develop new medicines, devices, and diagnoses for this therapeutic area. Conversely, inflammatory disease trials had the least A&G trials at 20.7%, which might indicate that industry is more interested in development in this area.

According to analyses of the three therapeutic areas investigated, A&G trials included primarily small (\<100 participants) and early-phase trials. This suggests that these trials are likely to be broad, exploratory ones and very heterogeneous. Brain disease and endocrine tumor areas had a concentration of early-phase trials and/or feasibility studies and were more often to be open-label, single-arm studies. Interestingly, endocrine tumor studies were particularly characterized by female-only trials for ovarian or breast cancer, which indicates an increasing trend in the development of new ovarian and breast cancer treatments in 2010. Meanwhile, the characteristics of cardiovascular disease trials revealed two trends, a tendency toward early-phase trials and/or feasibility studies, similar to the other two areas, and a trend toward observational trials with \> 500 participants and the use of active controls.

In Japan, the number of IITs (56 trials over the 8-year study period) was quite a bit smaller than those registered in [ClinicalTrials.gov](http://ClinicalTrials.gov). Japanese IITs were dominated by interventional treatment studies in early phase with few participants. About 20% of IITs were late-phase studies with more than 100 participants. Japanese IITs were mostly characterized by open-label, single group, non-randomized, and uncontrolled studies, meaning that the IITs in Japan were focused on more exploratory and feasible studies than those in the other countries. However, this conclusion is based on only about 60 trials beginning in 2004; more long-term observation studies are needed. Overall, most Japanese IITs were early phase and small trials. This characteristic appears no different to IITs in [ClinicalTrials.gov](http://ClinicalTrials.gov). Nevertheless, there is a large difference in the number of IITs between Japan and other countries. No single factor that is likely to affect the number of Japanese IITs was found in this study. Some reasons for the low number of IITs are thought to include few funding opportunities and a poor quality assurance structure \[[@pone.0148455.ref003],[@pone.0148455.ref008]\]; however it is the author's opinion that the cause fundamentally lies within the clinical trial system in Japan. The number of Japanese IITs could be increased by improving the clinical trial environment or key areas within academia.

The first area in which Japan must improve is its clinical trial system. There are actually two IIT systems in Japan, one for IND and another for non-IND trials. IND trials are undertaken in accordance with GCP, with an IND application submitted to the MHLW. These trials are regulated and monitored in the same way as commercial trials and are reported monthly to the Institutional Review Board and the Pharmaceuticals and Medical Devices Agency in cases of safety issues. With few professionals available to operate clinical trials, such requirements present large hurdles for academia to overcome because they are often time-consuming and involve much paperwork and high costs. By contrast, non-IND trials are conducted under the Guidelines for Clinical Research issued by the MHLW in 2003, which do not require submission of an application \[[@pone.0148455.ref009]\]. The requirements for conducting non-IND IITs are not as stringent as those for IND trials; however, annual reporting to the research ethics committee is required, as well as to the MHLW for safety issues. Nevertheless, these requirements involve less time, less paperwork, and lower cost than IND trials. It is therefore easier for academic institutions to conduct non-IND trials, even with few staff, which has resulted in over 18,000 non-IND trials, according to the UMIN-CTR, since its establishment in 2005 \[[@pone.0148455.ref010]\]. The current environment is likely one reason for the small number of IITs for IND. However, non-IND trials are not performed in line with GCP. Therefore, the data from non-IND trials are not valid for new indications for approved drugs because of poorer data quality, owing to the less stringent requirements for non-IND trials regarding paperwork, research processes, and quality assurance. Conducting non-IND trials might provide some new evidence, but it is not useful in clinical practice.

Therefore, non-IND trials that do not follow GCP should be closed down immediately, and a review of the current Japanese IND-type IIT system should be carried out, with the aim to make it more efficient thereby simplifying the conduct of IND trials. Such actions could greatly improve the current clinical trial situation in Japan by increasing the number of IND-type IITs performed, through eliminating the need for clinical trial experts and the involvement of regulatory authorities. Before such implementation, however, effective ways to reduce paperwork, costs, and the time required to address regulatory issues must be considered. The Japanese government has created several national programs to build support institutions within academia that provide clinical trial services such as data management, statistical analysis, and monitoring. These programs could also be helpful for investigators in conducting IND trials \[[@pone.0148455.ref011]--[@pone.0148455.ref014]\].

There are some limitations in this study. One is that there were some missing data despite mandatory data requirements by [ClinicalTrials.gov](http://ClinicalTrials.gov) and the Japanese registries. Recent reports have described that the [ClinicalTrials.gov](http://ClinicalTrials.gov) database could contain some quality issues owing to self-reporting by sponsors \[[@pone.0148455.ref015]\]. Another limitation is the focus only on 1-year characteristics of A&G trials registered in [ClinicalTrials.gov](http://ClinicalTrials.gov) by sponsors from all over the world. In addition, there were too few Japanese IITs to clearly demonstrate trial characteristics. The EudraCT database was not open to the public at the time this article was written; therefore, trial characteristics in European countries were unavailable. A comparison that includes European registries should be made in the near future.

Conclusion {#sec012}
==========

In this study, new and revised clinical trials sponsored by A&G that were registered in [ClinicalTrials.gov](http://ClinicalTrials.gov) during 2010 averaged about 40% of all sponsor-identified trials. According to analysis of the three main therapeutic areas, these A&G trials were nearly all early phase studies for the purpose of treatment, with a small number of participants. There were around 60 Japanese IITs over an 8-year period beginning in 2004. These trials were also mostly early-phase studies for the purpose of treatment, with a small number of participants. The characteristics of IITs between Japan and other countries exhibited no great differences, although there was a large difference in the number of Japanese IITs compared with other countries. Japan's IIT system and clinical trial environment should be immediately reviewed, to close this gap.
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